Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung.
Fifty consecutive patients with extensive non-small cell carcinoma of the lung were randomized to one of two chemotherapeutic regimens. Twenty-three patients (group 1) received cyclophosphamide (600 mg/mg(2)), doxorubicin (40 mg/m(2)), and cisplatin (50 mg/m(2)) every 3 weeks; 27 patients (group 2) received cyclophosphamide (600 mg/m(2)), doxorubicin (40 mg/m(2)), and cisplatin (100 mg/m(2)) every 3 weeks. The objective response rates were 4% and 7% in groups 1 and 2, respectively. Median survival duration was 15.2 weeks (group 1) and 21.7 weeks (group 2; P greater than or equal to 0.3). Hematologic toxicity was minimal in group 1 and moderate in group 2. Renal toxicity was moderate in group 2 only. Combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin as used in this study is not superior to previous studies in this institution using cyclophosphamide as a single agent.
D000368:Aged; D001772:Blood Cell Count; D002945:Cisplatin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D011336:Probability; D011897:Random Allocation; D013997:Time Factors
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin